weight loss glp-1 agonists Comparing Ozempic, Wegovy and Other Drugs GLP-1 Drug Savings: A Complete

Gastrointestinal disorders, primarily nausea, were the most common treatment-emergent adverse events, which could be mitigated with slower dose escalation

Borthwick Diabetes Research Centre, Lister Hospital, Coreys Mill Ln, Stevenage SG1 4AB, UK Tel: +44-1438-285972, Fax: +44-1438-284150, E-mail: [email protected] Copyright 2024 Korean Endocrine Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited

This increased risk was confined to women using GLP-1 receptor agonists for diabetes treatment (liraglutide aOR 1.70, 95% CI 1.172.48

Body weight and food intake were subsequently monitored daily in the afternoon

Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: A randomised, double-blind, placebo-controlled, clinical trial